HOME >> BIOLOGY >> NEWS
Failure to meet United Nations sanitation target could affect millions of the world's poorest

Worldwide, billions of people lack access to a reliable source of safe drinking water and basic sanitation facilities. To address the problem, the United Nations established the Target 10 initiative, which aims to halve the proportion of people without sustainable access to safe drinking water and basic sanitation by 2015.

Target 10 was launched in 2000 as part of the U.N. Millennium Development Goals initiative, a global effort by member nations "to meet the needs of the world's poorest." The target is based on data from 1990, when 20 percent of the global population lacked a safe source of drinking water and 45 percent had no access to sanitation facilities. Now, halfway to the deadline, experts warn that the United Nations is on track to achieve only part of the Target 10 objective.

"The target of reducing to one-half the proportion of people who do not have access to improved water supplies will probably be met," said Jennifer "Jenna" Davis, assistant professor of civil and environmental engineering and a fellow at the Woods Institute for the Environment at Stanford. "[But] on the sanitation side, we're in big trouble. We're probably going to miss that goal by 500 million people."

Sanitation, the 'poor cousin'

Today, more than 1 billion people worldwide live without a safe drinking water supply and more than 2.5 billion people don't have basic hygiene facilities, according to the United Nations. Davis, a participant in the U.N. Millennium Project task force, attributed the lack of success in reaching the sanitation target to a myriad of reasons, starting at the level of the individual. "If you have a lack of resources and you have to decide whether to invest in having clean water or in having sanitation facilities, you're going to be going for the water," she said. "It's a rational prioritization in the short term. Everyone can figure out a place to defecate if forced to do so."

Politics also has contri
'"/>

Contact: Mark Shwartz
mshwartz@stanford.edu
650-723-9296
Stanford University
15-Mar-2007


Page: 1 2 3

Related biology news :

1. Failure of scout cells may lead to cancer in transplant patients
2. Failure to dispose of unneeded cells during development linked to cancer
3. Takeda and Tap to promote Sucampos Amitiza in the United States
4. European Union outpaces United States on chemical safety
5. United Nations Biosafety meeting to take place in Brazil
6. Ferry-linked water monitoring system becomes new model for United States
7. Introductory geoscience enrollments in the United States
8. Researchers unlock mysteries of toxic metals in the largest contaminated site in United States
9. Huntingtons disease study shows animal models on target
10. New target for HIV/AIDS drugs and vaccine discovered
11. When off-target is right on

Post Your Comments:
(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ... Competitive Profiles - NEC" report to their offering. ... will continue to supply a range of IT security ... company focus on the development of a Big Data ... in the Asia-Pacific region is ...
(Date:4/8/2015)... , April 8, 2015  Infinisource, a ... and services, and Morpho, a leading supplier of ... to produce the market,s most advanced biometrically-enabled time ... iSolved NXG time clock is setting a bold, ... labor data for the small and mid-size employer. ...
(Date:4/2/2015)... 2, 2015 In the ... far outperforms the strongest competitors, showing outstanding performance ... the system is capable of a throughput of ... up to be ten times faster than most ... performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
(Date:4/16/2015)... (PRWEB) April 16, 2015 Regis Technologies ... American Association for Cancer Research (AACR) annual meeting. Regis ... Convention Center, starting Saturday, April 18, in Philadelphia and ... claim to title of the oldest and largest organization ... fellowships and grants, and partners with survivors to promote ...
(Date:4/16/2015)... (PRWEB) April 16, 2015 ... at Charlotte (UNC Charlotte) spin-out company, announced today ... Cooper, Ph.D., M.D., as Chief Operating Officer (COO). ... of experience in developing clinical diagnostic and biotechnology ... infectious disease. , Cooper’s extensive career transcends the ...
(Date:4/16/2015)... 16, 2015  In recognition of World Hemophilia Day, ... groups to illuminate more than 15 prominent landmarks red throughout ... Boston,s Zakim Bridge and Prudential Tower, ... Mercedes-Benz Superdome and Denver,s ... of April 17, and coincide with hemophilia community events in ...
(Date:4/16/2015)... April 16, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... U.S. joint venture with G-treeBNT (ReGenTree LLC) has ... clinical trial for the orphan disorder, neurotrophic keratopathy ... dry eye syndrome (DES) in the U.S.  Both ... RGN-259/GBT201, this year.  Each of these eye disorders ...
Breaking Biology Technology:Regis Technologies Joins American Association for Cancer Research Annual Meeting 2OncoTAb Names Dr. David L. Cooper as COO 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 3Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5
Cached News: